4-Chloro-N-(6,7-dimethoxy-4-oxo-1,4-dihydro-2-quinazolinyl)benzamide | 700861-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-Chloro-N-(6,7-dimethoxy-4-oxo-1,4-dihydro-2-quinazolinyl)benzamide
• 英文别名: 4-chloro-N-(6,7-dimethoxy-4-oxo-1,4-dihydroquinazolin-2-yl)benzamide；4-chloro-N-(6,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)benzamide
• CAS: 700861-24-1
• 化学式: C₁₇H₁₄ClN₃O₄
• mdl: MFCD03903805
• 分子量: 359.769
• InChiKey: QLADIYYPOGXCOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  89
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-4,5-二甲氧基苯甲酸甲酯 、 4-氯-N-氰基苯甲酰胺 以 1,4-二氧六环 为溶剂， 以60%的产率得到4-Chloro-N-(6,7-dimethoxy-4-oxo-1,4-dihydro-2-quinazolinyl)benzamide
  参考文献：
  名称：

  氰胺与邻氨基苯甲酸酯、2-氨基苯基酮和 2-(3-氧代哌嗪-2-基)乙酸甲酯的环化反应

  摘要：

  芳基-、芳酰基-和（4,6-二甲基嘧啶-2-基）氰胺与邻氨基苯甲酸甲酯、2-氨基苯基酮和2-（3-氧代哌嗪-2-基）乙酸甲酯环化生成2-氨基- 3,4-二氢喹唑啉-4-one、2-氨基喹唑啉和6-氨基-1,3,4,8,9,9a-六氢-2H-吡嗪并[1,2-c]嘧啶-1,8-二酮衍生品，分别。

  DOI：

  10.1007/s11172-008-0025-8

文献信息

• TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS
  申请人：Schwiebert Erik M.

  公开号：US20140073632A1

  公开（公告）日：2014-03-13

  Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of screening for CFTR corrector compounds are also described herein. The methods of screening include contacting a cell that endogenously expresses a CFTR mutation with the compound to be screened and detecting a rescue of halide efflux from the cell.
• US9221840B2
  申请人：——

  公开号：US9221840B2

  公开（公告）日：2015-12-29
• [EN] TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS<br/>[FR] TRAITEMENT DES TROUBLES LIÉS AU REPLIEMENT DES PROTÉINES AVEC DES CORRECTEURS DE CFTR À PETITE MOLÉCULE
  申请人：DISCOVERYBIOMED INC

  公开号：WO2012158913A2

  公开（公告）日：2012-11-22

  Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of screening for CFTR corrector compounds are also described herein. The methods of screening include contacting a cell that endogenously expresses a CFTR mutation with the compound to be screened and detecting a rescue of halide efflux from the cell.